Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

Refer a Patient to MSKCC: mskcc.org/refer

 

ASCO 2022 Conference Coverage
G

ASCO 2022: A Phase II Study of Gem + Cis Chemo in MIBC With Bladder Preservation for Patients Whose Tumors Harbor Deleterious DNA Damage Response Gene Alterations (Alliance A031701)

By ASCO 2022 Conference Coverage FEATURING Gopa Iyer
By ASCO 2022 Conference Coverage FEATURING Gopa Iyer
123 views
June 8, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter
Genitourinary
06:55
Insights from 2024 ASCO® GU Annual Meeting

ASCO® GU 2024 Insights: "HER2 and PD-L1 Immunohistochemistry Ex…

Feat. D. Aggen
08:56
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "MEDI5752 (Volrustomig) in the 1L Treatment…

Feat. M. Voss
24:28
OncoAlert

The Best of GU Radiation Oncology

Feat. S. McBride
46:48
University of Colorado Cancer Center

Theranostics and the Changing Face of Prostate Cancer

Feat. M. Morris
08:05
ASCO 2022 Conference Coverage

ASCO 2022: A Phase II Study of Gem + Cis Chemo in MIBC With Bladder …

Feat. G. Iyer
44
Memorial Sloan Kettering Cancer Center

Lecture Summary - Results of Phase II Clinical Trial of Cabozantinib…

Feat. C. Lee
07:31
Memorial Sloan Kettering Cancer Center

Results of Phase II Clinical Trial of Cabozantinib + Nivolumab for A…

Feat. C. Lee
06:49
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on Gem & Cis as Neoadjuvant Chemo in High-Grade UTU…

Feat. W. Yip
06:24
ecancer

ASCO 2021 Update on mCRPC: VISION Trial Data on Lutetium-177-PSMA-617

Feat. M. Morris
04:46
Memorial Sloan Kettering Cancer Center

2020 Update on mRCC: Lenvatinib + Pembro After CPIs: Is There a Bene…

Feat. C. Lee